YESAFILI
- Product NDC
- 83257-035
- 11-digit product format
- 832570035
- Labeler code
- 83257
- Product ID
- 83257-035_783e32b7-6349-2a90-55c2-9e040cfe854e
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- aflibercept-jbvf
- Dosage form
- INJECTION, SOLUTION
- Route
- INTRAVITREAL
- Labeler
- Biocon Biologics Inc.
- Application
- BLA761274
- Marketing category
- BLA
- Marketing start
- 2026-08-03
- Substance
- AFLIBERCEPT
- Active strength
- 2 mg/.05mL
- Pharmacologic classes
- Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- YESAFILI
- Listing expiration
- 2027-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| AFLIBERCEPT | 2 mg/.05mL |
Purple Book Biologic Products#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 761274 | Yesafili | aflibercept-jbvf | 351(k) Interchangeable | Rx | 2026-09-01 |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|
| 83257-035-41 | 83257003541 | 1 SYRINGE, GLASS in 1 CARTON (83257-035-41) / .05 mL in 1 SYRINGE, GLASS | 2026-08-03 | No | No | Current |